MedTrace Logo

Natrunix Versus Methotrexate in Rheumatoid Arthritis

NCT05363917 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-05-06

No results posted yet for this study

Summary

Phase II Double-Blinded, Placebo-Controlled Randomized Study Examining the Safety and Efficacy of Natrunix versus MTX (+folate) for the Treatment of Rheumatoid Arthritis

Conditions

Interventions

DRUG

Natrunix with MTX placebo (+folate)

True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α

DRUG

Natrunix placebo with MTX (+folate)

Natrunix placebo with MTX (+folate)

Sponsors & Collaborators

  • XBiotech, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2022-12-15
Completion
2023-02-15
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05363917 on ClinicalTrials.gov